BIOMAT Database Logo BIOMAT Database Logo

1,2,3-Thiadiazole substituted pyrazolones as potent KDR/VEGFR-2 kinase inhibitors. 2007

Rabindranath Tripathy, and Arup Ghose, and Jasbir Singh, and Edward R Bacon, and Thelma S Angeles, and Shi X Yang, and Mark S Albom, and Lisa D Aimone, and Joseph L Herman, and John P Mallamo
Cephalon Inc., 145 Brandywine Parkway, West Chester, PA 19380, USA. rtripath@cephalon.com

KDR kinase inhibition is considered to play an important role in regulating angiogenesis, which is vital for the survival and proliferation of tumor cells. Recently we disclosed a structure-based kinase inhibitor design strategy which led to the identification of a new class of VEGFR-2/KDR kinase inhibitors bearing heterocyclic substituted pyrazolones as the core template. Instability in a rat S9 preparation and poor iv PK profiles for most of these inhibitors necessitated exploration of new pyrazolones to identify new analogs with improved metabolic stability. Optimization of the heterocyclic moiety led to the identification of the thiadiazole series of pyrazolones (D) as potent VEGFR-2/KDR kinase inhibitors. SAR modifications, kinase selectivity profiling, and structural elements for improved PK properties were explored. Oral bioavailability up to 29% was achieved in the rat. Modeling results based on the Glide XP docking approach supported our postulation regarding the interaction of the lactam segment of the pyrazolones with the hinge region of the KDR kinase.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D011480 Protease Inhibitors Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). Antiprotease,Endopeptidase Inhibitor,Endopeptidase Inhibitors,Peptidase Inhibitor,Peptidase Inhibitors,Peptide Hydrolase Inhibitor,Peptide Hydrolase Inhibitors,Peptide Peptidohydrolase Inhibitor,Peptide Peptidohydrolase Inhibitors,Protease Antagonist,Protease Antagonists,Antiproteases,Protease Inhibitor,Antagonist, Protease,Antagonists, Protease,Hydrolase Inhibitor, Peptide,Hydrolase Inhibitors, Peptide,Inhibitor, Endopeptidase,Inhibitor, Peptidase,Inhibitor, Peptide Hydrolase,Inhibitor, Peptide Peptidohydrolase,Inhibitor, Protease,Inhibitors, Endopeptidase,Inhibitors, Peptidase,Inhibitors, Peptide Hydrolase,Inhibitors, Peptide Peptidohydrolase,Inhibitors, Protease,Peptidohydrolase Inhibitor, Peptide,Peptidohydrolase Inhibitors, Peptide
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001345 Autoradiography The making of a radiograph of an object or tissue by recording on a photographic plate the radiation emitted by radioactive material within the object. (Dorland, 27th ed) Radioautography
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D013050 Spectrometry, Fluorescence Measurement of the intensity and quality of fluorescence. Fluorescence Spectrophotometry,Fluorescence Spectroscopy,Spectrofluorometry,Fluorescence Spectrometry,Spectrophotometry, Fluorescence,Spectroscopy, Fluorescence
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

Rabindranath Tripathy, and Arup Ghose, and Jasbir Singh, and Edward R Bacon, and Thelma S Angeles, and Shi X Yang, and Mark S Albom, and Lisa D Aimone, and Joseph L Herman, and John P Mallamo
Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors.
October 2019, European journal of medicinal chemistry,
Rabindranath Tripathy, and Arup Ghose, and Jasbir Singh, and Edward R Bacon, and Thelma S Angeles, and Shi X Yang, and Mark S Albom, and Lisa D Aimone, and Joseph L Herman, and John P Mallamo
The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity.
April 2016, European journal of medicinal chemistry,
Rabindranath Tripathy, and Arup Ghose, and Jasbir Singh, and Edward R Bacon, and Thelma S Angeles, and Shi X Yang, and Mark S Albom, and Lisa D Aimone, and Joseph L Herman, and John P Mallamo
Potent 2-[(pyrimidin-4-yl)amine}-1,3-thiazole-5-carbonitrile-based inhibitors of VEGFR-2 (KDR) kinase.
March 2006, Bioorganic & medicinal chemistry letters,
Rabindranath Tripathy, and Arup Ghose, and Jasbir Singh, and Edward R Bacon, and Thelma S Angeles, and Shi X Yang, and Mark S Albom, and Lisa D Aimone, and Joseph L Herman, and John P Mallamo
Evaluation of indazole-based compounds as a new class of potent KDR/VEGFR-2 inhibitors.
September 2008, Bioorganic & medicinal chemistry letters,
Rabindranath Tripathy, and Arup Ghose, and Jasbir Singh, and Edward R Bacon, and Thelma S Angeles, and Shi X Yang, and Mark S Albom, and Lisa D Aimone, and Joseph L Herman, and John P Mallamo
Development and strategies of VEGFR-2/KDR inhibitors.
September 2012, Future medicinal chemistry,
Rabindranath Tripathy, and Arup Ghose, and Jasbir Singh, and Edward R Bacon, and Thelma S Angeles, and Shi X Yang, and Mark S Albom, and Lisa D Aimone, and Joseph L Herman, and John P Mallamo
Discovery of a New Series of Naphthamides as Potent VEGFR-2 Kinase Inhibitors.
May 2014, ACS medicinal chemistry letters,
Rabindranath Tripathy, and Arup Ghose, and Jasbir Singh, and Edward R Bacon, and Thelma S Angeles, and Shi X Yang, and Mark S Albom, and Lisa D Aimone, and Joseph L Herman, and John P Mallamo
Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships.
September 2002, Current topics in medicinal chemistry,
Rabindranath Tripathy, and Arup Ghose, and Jasbir Singh, and Edward R Bacon, and Thelma S Angeles, and Shi X Yang, and Mark S Albom, and Lisa D Aimone, and Joseph L Herman, and John P Mallamo
1,2,3-Triazole-totarol conjugates as potent PIP5K1α lipid kinase inhibitors.
May 2024, Bioorganic & medicinal chemistry,
Rabindranath Tripathy, and Arup Ghose, and Jasbir Singh, and Edward R Bacon, and Thelma S Angeles, and Shi X Yang, and Mark S Albom, and Lisa D Aimone, and Joseph L Herman, and John P Mallamo
Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors.
September 2007, Journal of medicinal chemistry,
Rabindranath Tripathy, and Arup Ghose, and Jasbir Singh, and Edward R Bacon, and Thelma S Angeles, and Shi X Yang, and Mark S Albom, and Lisa D Aimone, and Joseph L Herman, and John P Mallamo
The discovery of N-(1,3-thiazol-2-yl)pyridin-2-amines as potent inhibitors of KDR kinase.
June 2004, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!